CN106890196A - Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared - Google Patents

Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared Download PDF

Info

Publication number
CN106890196A
CN106890196A CN201710223448.3A CN201710223448A CN106890196A CN 106890196 A CN106890196 A CN 106890196A CN 201710223448 A CN201710223448 A CN 201710223448A CN 106890196 A CN106890196 A CN 106890196A
Authority
CN
China
Prior art keywords
clostridium butyricum
cfu
preparation
bifidobacterium
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710223448.3A
Other languages
Chinese (zh)
Inventor
崔云龙
赵婀姿
李洪福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Eastsea Pharmaceutical Co ltd
Original Assignee
Qingdao Eastsea Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Eastsea Pharmaceutical Co ltd filed Critical Qingdao Eastsea Pharmaceutical Co ltd
Priority to CN201710223448.3A priority Critical patent/CN106890196A/en
Publication of CN106890196A publication Critical patent/CN106890196A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared, specifically prevented with clostridium butyricum or treat Parkinson's, reduce Parkinsonian symptoms.

Description

Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared
Technical field
The present invention relates to application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared, butyric acid shuttle is specifically used Bacterium prevents or treatment Parkinson's, reduces Parkinsonian symptoms.
Background technology
Parkinson's (PD), i.e. shaking plasy is common central nervous system degenerative disease in the elderly at present, It is the second common nerve degenerative diseases for being only second to Alzheimer disease.Parkinson's it is clinical with static tremor, myotonia, Bradykinesia, posture abnormal gait are primary symptom, are showed with autonomic nervous function involvement, decrease of cognitive function etc. more.The disease rises It is sick slow, gradually develop, initial symptoms are not often noted by people, myotonia companion's catalepsy that the later stage mostly occurs serious, Ultimately result in and be unable to leave the bed, have a strong impact on patients ' life quality and shorten the existence life-span.Existing China Parkinsonian number is about 2000000, annual China's neopathy number is estimated more than 100,000.China gradually steps into aging society, and the elderly's number is drastically Increase, the sick incidence of disease rises therewith.
The current remedy measures of Parkinson's are mainly drug therapy.Current western medicine mainly uses levodopa class system Agent, is described as " goldstandard " of PD drug therapies, but occurs curative effect after 2~5 years in medication and go down, motor fluctuations, with move be more The complication of characteristic.Receive the extension of Western medicine therapy time with patient, its symptom is gradually difficult to control to, or even aggravate the state of an illness. The traditional Chinese medical science is disadvantageous in that medication by rule of thumb, without fixed prescription and consumption, and patient individual difference is big, doctor's clinical experience ginseng Difference is uneven, and crude drug source is different, using limitation, therefore is difficult to produce good clinical effectiveness.
The present inventor has found that clostridium butyricum can effectively prevent or treat Parkinson's by research, and safety is not any Toxic and side effect, effect is better than Bifidobacterium, and has no that correlative study is reported, spy applies for this patent of invention.
The content of the invention
It is an object of the invention to provide a kind of preparation that can prevent or treat Parkinson's, said preparation is by clostridium butyricum system Into.
The preparation of preparation of the invention is implemented preferably through following step, but is not limited to this preparation technology, known The preparation technology that can be realized can be with：The sample that may contain clostridium butyricum is taken, then sample is placed in sterilizing anaerobism bottle, Nitrogen is blown into while being sufficiently mixed, is therefrom taken rapidly in the dilution that 2 grams of samples add 18mL sterilizings, be blown into nitrogen simultaneously fully Mix, in aseptic operating platform, carry out 10-1、10-2、10-3、10-4, 10-5, 10-6, 10-7Gradient dilution, takes 10-5, 10-6, 10-7 Three dilution gradients, are respectively coated on clostridium butyricum selectivity single bacterium colony and separate on solid medium, are placed in anaerobic jar, anaerobism Cultivated 48 hours at 37 DEG C, the single bacterium colony that selection is grown fine is inoculated in liquid amplification culture medium respectively, is placed in anaerobic jar, Amplification cultivation 48 hours at 37 DEG C of anaerobism.It is after gained medium centrifugal (12000rpm) is isolated into thalline, thalline freezing is true Sky dry, modulate and dry bacterium powder, then carry out strain idenfication and toxicity test, by be accredited as clostridium butyricum dry bacterium powder by Need ratio to add auxiliary material and be made the various formulations such as tablet, capsule, powder, pulvis or liquid preparation, can also add other viable bacterias Or the oligosaccharide such as FOS plays synergy.
Clostridium butyricum selectivity single bacterium colony separates solid medium and is preferably but not limited to：Purified water 1L, peptone 40.0g, Na2HPO45.0g, K2HPO41.0g, NaCl 2.0g, MgSO40.1g, glucose 2.0g, agar 25.0g, adjust pH 7.6,116 DEG C sterilize 20 minutes, treat that it is cooled to 50 DEG C or so, add yolk liquid 50.0mL, add final concentration of 200 μ g/mL's Aerosporin, adds the neomycin of the μ g/mL of final concentration 200, and after fully mixing, dispensing is in plate.
Clostridium butyricum liquid amplification culture medium is preferably but not limited to：Purified water 1L, tryptone 10.0g, beef extract 10.0g, yeast extract 3.0g, glucose 5.0g, NaCl 5.0g, soluble starch 1.0g, cysteine hydrochloride 0.5g, vinegar Sour sodium 3.0g, agar 0.5g, adjust pH 6.6-7.0,121 DEG C, sterilize 15 minutes.
To be further elaborated with the present invention, inventor is separated using the above method by clostridium butyricum selectivity single bacterium colony Solid medium is separated and identifies avirulent clostridium butyricum, and clostridium butyricum of the present invention is not limited to illustrate this hair Bright described bacterium, as long as avirulent clostridium butyricum is of the present invention, within the scope of the present invention.
Clostridium butyricum of the present invention is preferably but not limited to clostridium butyricum DF96101 deposit numbers CGMCC 0313.1 or fourth Sour clostridium QA-08 deposit numbers CGMCC 2303.
The present invention implements the bacteriological quality of the clostridium butyricum preferably used in explanation：
1st, to illustrate the invention, the present invention is clostridium butyricum DF96101 preservations using the clostridium butyricum that the above method is separate Numbering CGMCC 0313.1 or clostridium butyricum QA-08 deposit numbers CGMCC 2303.
2nd, colonial morphology
Micro- sem observation：Long 3.0-6.0 microns, wide 0.6-1.2 microns, straight-bar or fusiform bacterium, Gram-positive are produced Gemma, spore owes end life.
Plate morphology：Bacterium colony is circular, and edge is irregular, and slightly convex, opaque, color is yellowish, mattness.
3rd, Physiology and biochemistry identification
Hydrogen sulfide:-；Indoles:-；Gelatin liquefaction:-；Ammonia:-；Nitrate reduction:-；Nagler's reaction:-；Urase:-；V- P is tested:-；Catalase:-；It is whether aerobic:Anaerobic.
4th, glycolysis experimental identification
Arabinose:+；Rhamnose:+；Cellobiose:+；D-glucitol:-；D-Fructose:+；Soluble starch:+；D- half Lactose:+；Sucrose:+；Glucose:+；Trehalose:+；Synanthrin:+；Xylose:+；Lactose:+；Gluconate (sodium):+；D (+) is sweet Dew sugar:+；Maltose:+；PEARLITOL 25C:+；Glycerine:+；D (+) raffinose:+；Ribose:+；Melezitose:+；Melibiose:+.
Clostridium butyricum of the present invention refers to bion living.
The present invention be the clostridium butyricum as stated above separate using effective dose as main active ingredient, according to certain Preparation process, adds conventional excipient, flavor enhancement, disintegrant, preservative, lubricant, wetting agent, binder, solvent, thickening The auxiliary materials such as agent, solubilizer, are made any formulation being adapted for use with, such as tablet, capsule, granule, powder, liquid system The formulations such as agent, pulvis.
Clostridium butyricum of the present invention is made active bacteria formulation as key agents active ingredient.
Meaning effective dose of the invention refer to the clostridium butyricum that as stated above separate according to it is described above alone or in combination Total viable count that the solid live bacteria preparation being made as key agents active ingredient is included cannot be below 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g.
Meaning effective dose of the invention refer to the clostridium butyricum that as stated above separate according to it is described above alone or in combination Total viable count that the liquid active bacteria formulation being made as key agents active ingredient is included cannot be below 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Preparation of the present invention be used alone including clostridium butyricum or with other drugs use in conjunction, especially including butyric acid shuttle Bacterium be used alone or with Bifidobacterium use in conjunction.
Bifidobacterium of the present invention refers to bion living.
In the preparation of Bifidobacterium use in conjunction of the present invention, the total viable count of Bifidobacterium that solid pharmaceutical preparation is included is not low In 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or The total viable count of Bifidobacterium that liquid preparation is included is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, highest can Reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Preventing or treating handkerchief gold due to being made preparation as main active ingredient present invention firstly discloses clostridium butyricum Application in gloomy disease, therefore application of the preparation containing above-mentioned clostridium butyricum in preventing or treating Parkinson's preparation belongs to this The protection domain of invention.
Clostridium butyricum of the present invention is respectively provided with the work of prevention or treatment Parkinson's when any formulation is made With.If being prepared into preparation containing clostridium butyricum composition in its component, in the mark such as its packaging or specification or at other As long as indicating or pointing out that there is the effect for preventing or treating Parkinson's on any propaganda material, then protection scope of the present invention is fallen into Within.
Clostridium butyricum of the present invention can be made medicine, health food, food or drink etc..
Specific embodiment
Preparation example explanation：The above-mentioned preparation to clostridium butyricum preparation is illustrated, here by clostridium butyricum It is specifically described as a example by DF96101 deposit numbers CGMCC 0313.1 or clostridium butyricum QA-08 deposit numbers CGMCC 2303, Preparation method those skilled in the art of other clostridium butyricum strain preparations are easy to grasp by the present embodiment, other formulations Preparation method those skilled in the art are easy to grasp by this implementation, no longer describe explanation one by one herein.Preparation method is not It is confined to described in the embodiment of the present invention, the known method that can reach preparation purpose can be so that the preparation explanation of embodiment is only It is the description of the invention, is not limiting the scope of the invention.
Prepare the preparation of the clostridium butyricum pulvis of embodiment 1
The preparation of 1 bacterium powder and the identification of strain
The fecal specimens of people are taken, then sample is placed in sterilizing anaerobism bottle, be blown into nitrogen while being sufficiently mixed, rapidly Therefrom take in the dilution that 2 grams of samples add 18mL sterilizings, be blown into nitrogen and fully mix simultaneously, in aseptic operating platform, carry out 10-1、10-2、10-3、10-4, 10-5, 10-6, 10-7Gradient dilution, takes 10-5, 10-6, 10-7Three dilution gradients, are respectively coated on junket Sour clostridium selectivity single bacterium colony is separated on solid medium, is placed in anaerobic jar, is cultivated 48 hours at 37 DEG C of anaerobism, selects growing way Good single bacterium colony is inoculated in liquid amplification culture medium respectively, is placed in anaerobic jar, amplification cultivation 48 hours at 37 DEG C of anaerobism. After gained medium centrifugal (12000rpm) is isolated into thalline, by thalline vacuum freezedrying, modulate and dry bacterium powder, then Carry out strain idenfication, clostridium butyricum be accredited as through Physiology and biochemistry, be clostridium butyricum DF96101 deposit numbers CGMCC 0313.1 or Clostridium butyricum QA-08 deposit numbers CGMCC 2303.
Clostridium butyricum DF96101 deposit numbers CGMCC 0313.1 or clostridium butyricum QA-08 deposit numbers CGMCC 2303 Prepared by bacterium powder, by clostridium butyricum DF96101 deposit numbers CGMCC 0313.1 or clostridium butyricum QA-08 deposit numbers CGMCC 2303 are inoculated into clostridium butyricum liquid amplification culture medium, amplification cultivation 48 hours at 37 DEG C of anaerobism.By gained medium centrifugal After (12000rpm) isolates thalline, by thalline vacuum freezedrying, modulate and dry bacterium powder, viable count is 1 × 109CFU/ More than g.
2 toxicity tests
2.1 animals and packet take 30 SPF rank mouse, and 6-8 week old, body weight 14-18g is randomized into clostridium butyricum 0313.1 group of CGMCC, 2303 groups of clostridium butyricum CGMCC and non-administered group, every group 10.2.2 prepare bacterium solution by above-mentioned difference Clostridium butyricum bacterium powder be modulated to be 1 × 10 containing bacterium number respectively with purified water9The bacterium solution of CFU/mL.
Each clostridium butyricum group of 2.3 methods and non-administered group give identical basal feed, and rearing conditions are consistent, respectively Clostridium butyricum group gavages clostridium butyricum bacterium solution 0.5mL daily, and non-administered group gavages purified water 0.5mL daily, feeds 14 days, observation Body weight and toxic reaction.
2.4 results
Each group mouse does not occur abnormal conditions, and chatter, spasm, ataxia, attitude exception do not occur, prominent without eyeball Go out, urination is normal, skin, breathing are normal, without death condition, have no toxic reaction.
3 are prepared into the formulations such as pulvis
It is non-toxic through experimental check, so that it may to be made clostridium butyricum strain after separating identification according to above-mentioned steps and method Bacterium powder, then addition relevant auxiliary materials are made various formulations as required, preferably according to the viable count of clostridium butyricum bacterium powder, add in proportion Plus starch is made pulvis, viable count is set to be not less than 1 × 107CFU/g, then packs.
Application effect embodiment explanation：
The present invention is with clostridium butyricum DF96101 deposit numbers CGMCC 0313.1 or clostridium butyricum QA-08 deposit numbers CGMCC 2303 is the application effect that representative illustrates clostridium butyricum, and bacterium powder is provided by Qingdao DongHai Pharmacy Co., Ltd.The present invention The middle Bifidobacterium for using comes from market products, the bifidobacteria viable bacteria that the public can buy.
Application effect embodiment 1：Application of the clostridium butyricum in Parkinson's are treated
It is prepared by 1 model group：
The week old of 1.1 experimental animal 8 male C57BL/6 mouse, 20~25g of body weight breeds purchased from the happy experimental animal of Jinan friend Co., Ltd.Adapt to raise one week before experiment：Natural lighting, 22 ± 2 DEG C of room temperature, freely absorbs food and water, and daily timing is more Feed is changed, well-ventilated excludes the interference of other stress factors.
1.2 preparation method C57BL/6 mouse inject MPTP (25mg/kg), while probenecid (250mg/kg) is given, weekly 2 times (3.5 days interval times) of administration, continuous 5 weeks.Set up murine chronic Parkinson disease model.
1.3 model groups prepare result modeling success.
2 drug therapies are tested：
2.1 experimental techniques choose the successful Parkinson disease mice 40 of modeling, the normal mouse 10 raised.Wherein It is normal to raise mouse for Normal group (n=10), Parkinson disease mice is randomly divided into clostridium butyricum (DF96101) and is controlled Treatment group, clostridium butyricum (QA-08) treatment group, Bifidobacterium treatment group, 4 groups of model control group (n=10).Each treatment group and control Group gives identical basal feed, and rearing conditions are consistent, and clostridium butyricum (DF96101, QA-08) and Bifidobacterium are treated Group is 1 × 10 using containing bacterium number6The bacterium solution of CFU/mL (modulating bacterium powder with 0.9% physiological saline) gavages 0.5mL, model control group 0.9% physiological saline 0.5mL, continuous 2 weeks are gavaged daily with Normal group group.Observation clostridium butyricum is to parkinsonian mouse row It is the influence learned, and is compared with Bifidobacterium.
2.2 Behavior evaluations carry out Behavior evaluation, including gait change (footprint reality after experiment terminates to experimental mouse Test) and autonomic activities change (mobile grid and counting of standing).Data carry out statistical analysis using SPSS 21.0.
3 results
3.1 gaits change (footprint experiment)
Compared with Normal group, Parkinson disease mice average step length reduces (P ＜ 0.01), and hind leg step width increases (P ＜ 0.01), (P ＜ 0.01) is increased by the time used by trogue, and difference is statistically significant.With Parkinson disease mice phase Than after clostridium butyricum DF96101 and QA-08 treatment, mouse average step length increases (P ＜ 0.05), and hind leg step width reduces (P ＜ 0.05) (P ＜ 0.05), is reduced by the time used by trogue, difference has statistical significance.With Bifidobacterium treatment group mouse phase Than clostridium butyricum DF96101 and QA-08 treatment groups Mice Mice average step length increases (P ＜ 0.05), and hind leg step width reduces (P ＜ 0.05) (P ＜ 0.05), is reduced by the time used by trogue, difference has statistical significance.Clostridium butyricum DF96101 treatment groups And QA-08 treatment groups between, mouse average step length, hind leg step width, by time no difference of science of statistics (P ＞ used by trogue 0.05).Clostridium butyricum can significantly improve the motion of parkinsonian mouse to the effect of being significantly improved of the gait of parkinsonian mouse Balanced capacity, and it is significantly higher than Bifidobacterium treatment group.It is shown in Table 1.
The different group mouse gait change statistical analyses of table 1
Group Number of cases Average step length (cm) Hind leg step width (cm) By the time (s) used by trogue
Normal group 10 6.17±0.32 2.23±0.57 10.33±2.23
Model control group 10 3.52±0.33 3.62±0.19 17.85±3.96
Bifidobacterium treatment group 10 4.21±0.58 3.35±0.60 15.99±2.55
Clostridium butyricum (DF96101) treatment group 10 5.26±0.43 2.67±0.36 12.87±2.47
Clostridium butyricum (QA-08) treatment group 10 5.31±0.20 2.70±0.57 13.39±2.98
3.2 autonomic activitieses change
Compared with Normal group, Parkinson disease mice movement grid number and standing number of times reduce (P ＜ 0.01), difference is statistically significant；It is small after clostridium butyricum DF96101 and QA-08 treatment compared with Parkinson disease mice Mouse moves grid number and standing number of times increases (P ＜ 0.05), and difference is statistically significant；With Bifidobacterium treatment group mouse phase Than clostridium butyricum DF96101 and QA-08 treatment groups mouse movement grid number and standing number of times increase (P ＜ 0.05), and difference has Statistical significance；Between clostridium butyricum DF96101 treatment groups and QA-08 treatment groups, mouse movement grid number and standing number of times are equal No difference of science of statistics (P ＞ 0.05).Clostridium butyricum can dramatically increase the autonomic activities of parkinsonian mouse, and its effect is significant is higher than Bifidobacterium.It is shown in Table 2.
The different group mouse autonomic activities change statistical analyses of table 2
4 discuss
The autonomic activities that Parkinson disease model group compares mouse with Normal group is substantially reduced, in disorder (the average step of gait Reduction long, hind leg step width are increased, are increased by the time used by trogue), and after being treated through clostridium butyricum, the autonomic activities of mouse shows Writing increases (P ＜ 0.05), and locomitivity is significantly improved, and average step length dramatically increases (P ＜ 0.05), and hind leg step width is substantially reduced (P ＜ 0.05), (P ＜ 0.05) is substantially reduced by the time used by trogue, and evident in efficacy be better than Bifidobacterium treatment group.Show junket Sour clostridium intervenes the Parkinsonian symptoms that can substantially reduce Parkinson disease mice.
Clostridium butyricum preparation can effectively prevent or treat Parkinson's, hence it is evident that reduce Parkinsonian symptoms, and without any Toxic and side effect, it is good using compliance, it is new method, the new breakthrough for preventing or treating Parkinson's.
Clostridium butyricum strain of the present invention used in implementation process is respectively on July 28th, 1997 and 2007 12 The moon 26 is in China Committee for Culture Collection of Microorganisms's common micro-organisms center (Datun Road, Chaoyang District, Beijing City, Chinese section Institute of microbiology of institute, postcode 100101) preservation, totally two following strains, but clostridium butyricum of the present invention is simultaneously It is not limited to both microorganism fungus kinds.
(1) Classification And Nomenclature：Clostridium butyricum Clostridium butyricum, preserve numbering 0313.1.
(2) Classification And Nomenclature：Clostridium butyricum Clostridium butyricum, preserve numbering 2303.
Above-mentioned two strain is survival through the microorganism Spot detection, testing result.

Claims (10)

1. application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared.
2. applied as described in claim 1, it is characterised in that the preparation is used alone or and other drugs including clostridium butyricum Use in conjunction.
3. applied as described in claim 1, it is characterised in that the preparation includes medicine, health food, food, drink.
4. applied as described in claim 1, it is characterised in that the clostridium butyricum refers to bion living.
5. applied as described in claim 1, it is characterised in that the clostridium butyricum includes clostridium butyricum DF96101 deposit numbers CGMCC 0313.1 or clostridium butyricum QA-08 deposit numbers CGMCC 2303.
6. applied as described in claim 2, it is characterised in that the preparation is used alone or and Bifidobacterium including clostridium butyricum Use in conjunction.
7. applied as described in claim 6, it is characterised in that the Bifidobacterium refers to bion living.
8. applied as described in claim 1, it is characterised in that prevention or treatment Parkinson's, reduce Parkinsonian symptoms.
9. the preparation as described in claim 1, it is characterised in that the total viable count of clostridium butyricum that solid pharmaceutical preparation is included is not less than 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid The total viable count of clostridium butyricum that preparation is included is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach 1×1012CFU/mL or 1 × 1012More than CFU/mL.
10. the preparation as described in claim 6, it is characterised in that the total viable count of Bifidobacterium that solid pharmaceutical preparation is included is not less than 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid The total viable count of Bifidobacterium that preparation is included is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach 1×1012CFU/mL or 1 × 1012More than CFU/mL.
CN201710223448.3A 2017-04-07 2017-04-07 Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared Pending CN106890196A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710223448.3A CN106890196A (en) 2017-04-07 2017-04-07 Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710223448.3A CN106890196A (en) 2017-04-07 2017-04-07 Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared

Publications (1)

Publication Number Publication Date
CN106890196A true CN106890196A (en) 2017-06-27

Family

ID=59193588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710223448.3A Pending CN106890196A (en) 2017-04-07 2017-04-07 Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared

Country Status (1)

Country Link
CN (1) CN106890196A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1446100A (en) * 2000-06-14 2003-10-01 阿勒根公司 Method for treating movement disorder
EP1521593A2 (en) * 2002-07-11 2005-04-13 Allergan, Inc. Transdermal botulinum toxin compositions
CN101134052A (en) * 2006-11-17 2008-03-05 青岛东海药业有限公司 Application of clostridium butyricum, condensate bacillus and bifidobacteria in the preparation of medicament for preventing and treating mouth ulcer
CN101496819A (en) * 2008-01-31 2009-08-05 青岛东海药业有限公司 Eubacterium, Clostridium preparation and use thereof
CN105012350A (en) * 2015-08-06 2015-11-04 温州医科大学 Probiotic clostridium butyricum strain
CN105055457A (en) * 2015-08-06 2015-11-18 温州医科大学附属第二医院 Drug for preventing and treating alzheimer's disease as well as preparation method and application of drug
CN105106244A (en) * 2015-08-06 2015-12-02 温州医科大学附属第二医院 Probiotics preparation for preventing and treating diabetic encephalopathy and method for preparing probiotics preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1446100A (en) * 2000-06-14 2003-10-01 阿勒根公司 Method for treating movement disorder
EP1521593A2 (en) * 2002-07-11 2005-04-13 Allergan, Inc. Transdermal botulinum toxin compositions
CN101134052A (en) * 2006-11-17 2008-03-05 青岛东海药业有限公司 Application of clostridium butyricum, condensate bacillus and bifidobacteria in the preparation of medicament for preventing and treating mouth ulcer
CN101496819A (en) * 2008-01-31 2009-08-05 青岛东海药业有限公司 Eubacterium, Clostridium preparation and use thereof
CN105012350A (en) * 2015-08-06 2015-11-04 温州医科大学 Probiotic clostridium butyricum strain
CN105055457A (en) * 2015-08-06 2015-11-18 温州医科大学附属第二医院 Drug for preventing and treating alzheimer's disease as well as preparation method and application of drug
CN105106244A (en) * 2015-08-06 2015-12-02 温州医科大学附属第二医院 Probiotics preparation for preventing and treating diabetic encephalopathy and method for preparing probiotics preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOINA GEORGESCU 等: "Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope?", 《CLINICAL INTERVENTIONS IN AGING》 *
姚庆和等: "帕金森病小鼠模型行为学检测方法的比较研究", 《中国实验动物学报》 *
彭小萍等: "彭小萍等", 《神经疾病与精神卫生》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof

Similar Documents

Publication Publication Date Title
CN102533618B (en) Lactobacillus plantarum CCFM8724 and application thereof
CN112088211A (en) Lactic acid bacteria and uses thereof
US8246946B2 (en) Treatment of bipolar disorder utilizing anti-fungal compositions
KR101104397B1 (en) Antiviral composition of fermented milk from lactic bacteria and its therof
RU2439145C2 (en) Strain of microorganism bacillus smithii tbm112 mscl p737 and its application as food or feed additive, or component of probiotic composition, and probiotic composition
WO2002067986A2 (en) Symbiotic regenerative agent
CN106389479A (en) Application of bacillus coagulans in preparing preparation for preventing or treating autism
CN106420840A (en) Application of Clostridium butyricum in preparation of preparations for preventing or treating depression
CN106474162A (en) Application in preparation prevention or treatment depression preparation for the Bacillus coagulans
CN103565848B (en) Application of bacillus coagulans in preparing preparations for preventing and treating helicobacter pylori infection
JP2019526258A (en) Leuconostoc forzapferii strain having alopecia prevention, hair growth promotion or sexual function improvement and composition containing the same
CN107854495A (en) Bacillus coagulans is preparing the application in reducing blood urine acid supplement
CN105624069A (en) Lactobacillus rhamnosus preparation and application thereof
CN111329884A (en) Application of lactobacillus plantarum BC299 in medicines and foods for treating inflammatory bowel diseases and psychogenic problems
CN112852670B (en) Bifidobacterium infantis DH231 and fermentation product, application and microecological preparation thereof
CN110325197A (en) For prevent hair loss or it is trichogenous include show lipolysis effect bacterial strain composition
CN106361777A (en) Application of clostridium butyricum in preparation of preparation for preventing or treating autism
CN102240304A (en) Formulation for breeding sea cucumbers, shrimps or abalones
CN106890196A (en) Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared
CN110090231A (en) Application of the clostridium butyricum in preparation prevention or treatment cholangiocarcinoma preparation
KR20180085667A (en) Composition for preventing depilation or improving hair growth comprising a stain having lipolysis ability
CN107836465A (en) A kind of Pesticidal combination using the zymotic fluid containing Metarhizium anisopliae and hydramethylnon as main active
Moore et al. The effect of an experimental chlorate product on Salmonella recovery of turkeys when administered prior to feed and water withdrawal
CN109394796A (en) Lactobacillus crispatus preparation and its application
Pingitore et al. Effect of lyophilization and storage temperature on the activity of salivaricin CRL 1328, a potential bioactive ingredient of a urogenital probiotic product

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170627

RJ01 Rejection of invention patent application after publication